Bispecific canine antibodies for treating atopic dermatitis

Bispecific antibodies targeting IL-31, IL-22, and IL-4Rα receptors in dogs with atopic dermatitis simultaneously address inflammation, skin barrier improvement, and pruritus, overcoming limitations of current therapies.

JP7875803B2Active Publication Date: 2026-06-18INTERVET INT BV
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
JP2022537140
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-10-15
Filing Date
2020-12-18
Publication Date
2026-06-18
Estimated Expiration
2040-12-18

AI Technical Summary

Technical Problem

Current therapies for atopic dermatitis in dogs fail to simultaneously address skin inflammation, improve skin barrier function, and provide rapid antipruritic action.

Method used

Development of bispecific antibodies comprising canine antipruritic, antiproliferative, and anti-inflammatory antibodies, which target IL-31, IL-22, and IL-4Rα receptors to regulate IL-4, IL-31, and IL-22 signaling, thereby reducing pruritus, inflammation, and improving skin barrier function.

Benefits of technology

The bispecific antibodies effectively reduce skin inflammation, improve skin barrier function, and provide rapid antipruritic effects in dogs with atopic dermatitis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007875803000013
    Figure 0007875803000013
  • Figure 0007875803000014
    Figure 0007875803000014
  • Figure 0007875803000015
    Figure 0007875803000015
Patent Text Reader

Abstract

The present invention provides a composition for treating canine atopic dermatitis, comprising a caninized anti-proliferative antibody, a caninized anti-pruritic antibody, and a caninized anti-inflammatory antibody. The present invention further relates to a bispecific antibody comprising a caninized anti-pruritic antibody and a caninized anti-proliferative antibody, or a bispecific antibody comprising a caninized anti-pruritic antibody and a caninized anti-inflammatory antibody.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Antibodies against canine interleukin-4 receptor alpha

    JP2018511322A

  • Caninized human antibodies against human and canine IL-4R alpha

    JP2019506146A

  • US10,093,731

  • Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

    US20150017176A1

  • Antibodies to Canine Interleukin-4 Receptor Alpha

    US20180346580A1